Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOVID-E vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Dysfunctional uterine bleeding,Endometriosis
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Metabolized via hepatic cytochrome P450 enzymes (CYP3A4) and conjugated with glucuronic acid and sulfate. Enterohepatic recirculation occurs.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethynodrel: 95-98% (albumin); mestranol: 97-99% (albumin and SHBG)
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethynodrel: 2-4 L/kg; mestranol: 3-5 L/kg; extensive tissue distribution
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: >90% for norethynodrel; mestranol: 40-60% (first-pass metabolism)
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential fluid retention
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic disease (Child-Pugh class C); dose reduction recommended in moderate impairment (Child-Pugh class B: use lowest effective dose)
No data available for fictional drug ALYACEN 777.
Not approved for use in pediatric patients; safety and efficacy not established
No data available for fictional drug ALYACEN 777.
No specific dose adjustment; caution due to increased risk of thromboembolic events and fluid retention in elderly patients
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events. Use contraindicated in women over 35 years who smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders, myocardial infarction, stroke, hepatic neoplasia, gallbladder disease, hypertension, and carbohydrate intolerance. Discontinue if jaundice, visual disturbances, or migraine occurs. Monitor blood pressure and liver function.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma, undiagnosed abnormal genital bleeding, known or suspected pregnancy, hepatic adenoma or carcinoma, impaired liver function, and smokers over 35 years.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions reported. Grapefruit juice may mildly increase estrogen levels but not clinically relevant. Maintain consistent dietary intake to avoid gastrointestinal upset.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects due to progestin and estrogen components. Second and third trimesters: Potential for feminization of male fetus, urogenital abnormalities, and possible long-term neurodevelopmental effects. Use contraindicated in pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk; M/P ratio not well established. Potential for adverse effects on infant including jaundice and breast enlargement. Avoid use during breastfeeding due to hormonal effects.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy; do not use. No dosing adjustments applicable as use is avoided. If exposure occurs, discontinue immediately and manage supportively.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Enovid-E (5 mg norethynodrel, 0.075 mg mestranol) is a first-generation combined oral contraceptive. Due to high estrogen dose, increased risk of thromboembolism; avoid in smokers over 35 and those with migraine with aura. Typically prescribed for contraception or menstrual disorders. Monitor for breakthrough bleeding and hypertension.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time for 21 days, then 7 days off.,Do not smoke while taking this medication, especially if over 35.,Watch for signs of blood clots: sudden leg swelling, chest pain, shortness of breath.,Use backup contraception if you miss a pill, especially during the first week.,This medication does not protect against HIV or other sexually transmitted infections.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOVID-E vs ALYACEN 777, answered by our medical review team.
ENOVID-E is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOVID-E and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOVID-E is: 5 mg orally once daily for 20 days starting on day 5 of menstrual cycle. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOVID-E and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOVID-E is classified as Category C. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects due to progestin and estrogen components. Second and third trimesters: . ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.